There is little academic information regarding the romantic lives of patients with psychotic disorders. Studies that do focus ...

People with Parkinson's disease (PD) who experience visual hallucinations have reduced brain responses to unexpected visual changes, a marker known as visual mismatch negativity (vMMN).

Reduced brain activity responding to unpredicted visual changes is a marker of psychosis in Parkinson's disease and a ...

Reduced brain activity responding to unpredicted visual changes is a marker of psychosis in Parkinson's disease and a ...

A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...

Bristol Myers' Cobenfy, recently approved by the FDA for schizophrenia, lacks a boxed warning, positioning it as a safer option. Analysts project peak sales of up to $5 billion if approved for ...

A consultant orthopaedic surgeon is dedicated to raising awareness about vitamin B12 deficiency following the tragic loss of his 21-year-old daughter.

Unlike other antipsychotics that treat schizophrenia, the agency approved Cobenfy without a “black box” warning on the ...

Available antipsychotic treatments work by blocking dopamine receptors. The new drug, Cobenfy, takes a different approach.

The loss of his 21-year-old daughter Georgina - who took her own life in 2019 - was a profound personal tragedy for ...

A new study suggests that LGBTQ+ individuals may face a higher risk of adverse brain health outcomes, including dementia and ...

The rate of antipsychotic drug use in nursing homes has remained stubbornly high. Experts are concerned about misuse.